About Editas Medicine, Inc.
https://www.editasmedicine.comEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.
CEO
Gilmore O'Neill
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 61
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:8.02M
Value:$17.8M
BLACKROCK INC.
Shares:7.78M
Value:$17.28M
VANGUARD GROUP INC
Shares:6.97M
Value:$15.46M
Summary
Showing Top 3 of 255
About Editas Medicine, Inc.
https://www.editasmedicine.comEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $7.54M ▲ | $32.09M ▼ | $-25.12M ▲ | -332.98% ▲ | $-0.28 ▲ | $-22M ▲ |
| Q2-2025 | $3.58M ▼ | $55.12M ▼ | $-53.23M ▲ | -1.49K% ▲ | $-0.63 ▲ | $-49.38M ▲ |
| Q1-2025 | $4.66M ▼ | $80.82M ▲ | $-76.09M ▼ | -1.63K% ▼ | $-0.92 ▼ | $-71.95M ▼ |
| Q4-2024 | $30.6M ▲ | $77.2M ▲ | $-45.4M ▲ | -148.33% ▲ | $-0.55 ▲ | $-32.98M ▲ |
| Q3-2024 | $61K | $64.13M | $-62.14M | -101.87K% | $-0.75 | $-60.54M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $165.65M ▼ | $201.75M ▼ | $188.3M ▼ | $13.45M ▼ |
| Q2-2025 | $178.5M ▼ | $210.58M ▼ | $191.39M ▼ | $19.19M ▼ |
| Q1-2025 | $220.96M ▼ | $263.65M ▼ | $201.23M ▼ | $62.42M ▼ |
| Q4-2024 | $269.91M ▲ | $341.59M ▲ | $207.31M ▲ | $134.27M ▼ |
| Q3-2024 | $265.09M | $327.57M | $151.93M | $175.63M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-25.12M ▲ | $-30.84M ▲ | $39.57M ▼ | $17.17M ▲ | $25.9M ▲ | $-31.28M ▲ |
| Q2-2025 | $-53.23M ▲ | $-50.21M ▼ | $42.65M ▼ | $7.41M ▲ | $-150K ▼ | $-50.21M ▼ |
| Q1-2025 | $-76.09M ▼ | $-47.8M ▲ | $56.39M ▲ | $-1.44M ▼ | $7.15M ▼ | $-47.91M ▲ |
| Q4-2024 | $-45.4M ▲ | $-50.76M ▲ | $30.96M ▼ | $55.51M ▲ | $35.71M ▲ | $-51.3M ▲ |
| Q3-2024 | $-62.14M | $-52.59M | $83.98M | $0 | $31.39M | $-55.51M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 Reportable Segment | $0 ▲ | $0 ▲ | $10.00M ▲ |
CEO
Gilmore O'Neill
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 61
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:8.02M
Value:$17.8M
BLACKROCK INC.
Shares:7.78M
Value:$17.28M
VANGUARD GROUP INC
Shares:6.97M
Value:$15.46M
Summary
Showing Top 3 of 255